Literature DB >> 16648659

Early colon cancer detected by 18F-FDG PET.

Kazuhiro Sakamoto1, Makoto Takahashi, Yukihiro Yaginuma, Yasunori Ishido, Takashi Matsuoka, Shuichi Sakamoto, Yuichi Tomiki, Toshiki Kamano.   

Abstract

Positron emission tomography (PET) is a noninvasive functional imaging modality that can disclose the presence of a malignant disease. It has recently been reported that PET may be useful to detect primary colorectal cancer (CRC). We present the case of a 47-yr-old man with early colon cancer detected by 18F-fluorodeoxyglucose (FDG) PET. The patient consulted us because of a positive fecal occult blood test and focal FDG uptake in the pelvic cavity detected at a physical check-up. After the usual work up, he was diagnosed as having a sigmoid polyp, 16 mm in diameter. Subsequently, colonoscopic polypectomy was carried out. The surgical specimen was histologically diagnosed as a well-differentiated adenocarcinoma, invading the submucosal layer with lymphatic invasion. Therefore, the involved portion of the sigmoid colon was laparoscopically resected. The FDG PET carried out 1 yr after the operation, showed no abnormal FDG uptake. PET can noninvasively detect an early colon cancer as small as in our patient, as well as other cancers in the whole body. Therefore, we consider it suitable as a screening examination.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16648659     DOI: 10.1385/IJGC:36:2:95

Source DB:  PubMed          Journal:  Int J Gastrointest Cancer        ISSN: 1537-3649


  18 in total

Review 1.  The role of positron emission tomography in the management of colorectal cancer.

Authors:  A N J Tutt; T A Plunkett; S F Barrington; M D Leslie
Journal:  Colorectal Dis       Date:  2004-01       Impact factor: 3.788

Review 2.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Authors:  P Rigo; P Paulus; B J Kaschten; R Hustinx; T Bury; G Jerusalem; T Benoit; J Foidart-Willems
Journal:  Eur J Nucl Med       Date:  1996-12

3.  The impact of FDG-PET on the management algorithm for recurrent colorectal cancer.

Authors:  T Arulampalam; D Costa; D Visvikis; P Boulos; I Taylor; P Ell
Journal:  Eur J Nucl Med       Date:  2001-10-20

4.  Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings.

Authors:  H Abdel-Nabi; R J Doerr; D M Lamonica; V R Cronin; P J Galantowicz; G M Carbone; M B Spaulding
Journal:  Radiology       Date:  1998-03       Impact factor: 11.105

5.  Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer.

Authors:  F L Flanagan; F Dehdashti; O A Ogunbiyi; I J Kodner; B A Siegel
Journal:  Ann Surg       Date:  1998-03       Impact factor: 12.969

6.  Relationship between Gastrointestinal F-18-fluorodeoxyglucose Accumulation and Gastrointestinal Symptoms in Whole-Body PET.

Authors:  Seok ki Kim; June Key Chung; Byung Tae Kim; Sun Jung Kim; Jae Min Jeong; Dong Soo Lee; Myung Chul Lee
Journal:  Clin Positron Imaging       Date:  1999-10

7.  Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings.

Authors:  Rozet Tatlidil; Hossein Jadvar; James R Bading; Peter S Conti
Journal:  Radiology       Date:  2002-09       Impact factor: 11.105

8.  Colorectal cancer screening in asymptomatic adults: the role of FDG PET scan.

Authors:  Yen-Kung Chen; Chia-Hung Kao; Alfred C Liao; Yeh-You Shen; Chen-Tau Su
Journal:  Anticancer Res       Date:  2003 Sep-Oct       Impact factor: 2.480

Review 9.  Use of positron emission tomography in oncology.

Authors:  J A Glaspy; R Hawkins; C K Hoh; M E Phelps
Journal:  Oncology (Williston Park)       Date:  1993-07       Impact factor: 2.990

10.  Early colon cancers detected by FDG-pet: a report of two cases with immunohistochemical investigation.

Authors:  Tatsuya Okuno; Kuang-I Fu; Yasushi Sano; Takayuki Yoshino; Kouji Murakami; Atsushi Ochiai; Shigeaki Yoshida
Journal:  Hepatogastroenterology       Date:  2004 Sep-Oct
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.